Document is current
Any future updates will be listed below
-
Authors
Srinivasan, Preethi
Bandlamudi, Chaitanya
Jonsson, Philip https://orcid.org/0000-0002-1537-0624
Kemel, Yelena https://orcid.org/0000-0002-5042-5651
Chavan, Shweta S.
Richards, Allison L.
Penson, Alexander V. https://orcid.org/0000-0003-2429-2370
Bielski, Craig M.
Fong, Christopher
Syed, Aijazuddin
Jayakumaran, Gowtham
Prasad, Meera
Hwee, Jason
Sumer, Selcuk Onur https://orcid.org/0000-0001-9726-9441
de Bruijn, Ino
Li, Xiang
Gao, JianJiong
Schultz, Nikolaus https://orcid.org/0000-0002-0131-4904
Cambria, Roy
Galle, Jesse
Mukherjee, Semanti
Vijai, Joseph https://orcid.org/0000-0002-7933-151X
Cadoo, Karen A.
Carlo, Maria I. https://orcid.org/0000-0002-4786-7408
Walsh, Michael F. https://orcid.org/0000-0001-5006-6778
Mandelker, Diana https://orcid.org/0000-0003-4154-0567
Ceyhan-Birsoy, Ozge
Shia, Jinru https://orcid.org/0000-0002-4351-2511
Zehir, Ahmet https://orcid.org/0000-0001-5406-4104
Ladanyi, Marc
Hyman, David M.
Zhang, Liying
Offit, Kenneth
Robson, Mark E. https://orcid.org/0000-0002-3109-1692
Solit, David B. https://orcid.org/0000-0002-6614-802X
Stadler, Zsofia K.
Berger, Michael F. https://orcid.org/0000-0003-3882-5000
Taylor, Barry S.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA227534)
Fund for Innovation in Cancer Informatics
- License Information
-
More Information
Article History
Received: 16 November 2020
Accepted: 9 September 2021
First Online: 5 November 2021
Competing interests
: K.A.C. reports advisory or consulting activities with AstraZeneca, MSD Ireland and GSK Ireland, and receives honoraria from Pfizer. M.I.C. has had an advisory role with Pfizer. D.M.H. received personal fees from Chugai Pharma, Boehringer Ingelheim, AstraZeneca, Pfizer, Bayer, Debiopharm Group and Genentech, and grants from AstraZeneca, Puma Biotechnology, Loxo Oncology (now owned by Eli Lilly) and Bayer. L.Z. received honoraria from Future Technology Research LLC, Roche Diagnostics Asia Pacific, BGI and Illumina, and has family members with leadership positions and ownership interests in Decipher Medicine. M.E.R. reports honoraria from Research to Practice, Intellisphere and Physician’s Education Resource; consulting and advisory activities for AstraZeneca, Daiichi-Sankyo, Epic Science, Merck and Pfizer (all uncompensated), and Change Healthcare; institutional research funding from AbbVie, AstraZeneca, Merck and Pfizer; and editorial services for AstraZeneca and Pfizer. D.B.S. has consulted with and received honoraria from Pfizer, Loxo/Lilly Oncology, Illumina, Vividion Therapeutics, Scorpion Therapeutics, Fore Biotherapeutics and BioBridge Pharma. Z.K.S. has an immediate family member who serves as a consultant in Ophthalmology for Alcon, Adverum, Gyroscope Therapeutics Ltd, Neurogene and RegenexBio, outside the submitted work. M.F.B. reports receiving research funding from Illumina and Grail and advisory board activities for Roche. B.S.T. reports advisory board activities for Boehringer Ingelheim and Loxo Oncology at Lilly, and research support from Genentech. The remaining authors declare no competing interests.
